NMT Medical
This article was originally published in The Gray Sheet
Executive Summary
Firm receives a grant from the National Institutes of Health to conduct a Phase I trial for its BioTrek bioactive patent foramen ovale closure device at the Dartmouth-Hitchcock Medical Center. The product joinsBioStar as NMT's second bioabsorbable closure technology. NMT is counting on the ongoing UK BEST study to support a CE mark for BioStar in the first half of the year (1"The Gray Sheet" March 7, 2005, p. 29)...